Karyopharm Therapeutics Inc.
KPTINASDAQHealthcare● Active
$8.74
+$0.24(+2.82%)
Market Cap$198074122
P/E Ratio—
52W High$10.99
52W Low$3.65
Karyopharm Therapeutics Inc. (KPTI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KPTI · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$1.24
Est. -$1.45 · +14.5%
Revenue
$0.04B
Est. $0.03B · +11.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
KPTI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$1.31 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$1.45 | -$1.24 | +14.5% | $0.04B | $0.03B | +11.7% |
| ▲ Q1 FY2026 | Feb 12, 2026 | -$2.26 | -$2.23 | +1.3% | $0.03B | $0.04B | -2.9% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -$3.47 | -$3.82 | -10.1% | $0.04B | $0.04B | +4.7% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$3.80 | -$4.32 | -13.7% | $0.04B | $0.04B | -4.1% |
| ▲ Q2 FY2025 | May 12, 2025 | -$4.21 | -$2.77 | +34.2% | $0.03B | $0.04B | -14.5% |
| ▲ Q1 FY2025 | Feb 19, 2025 | -$3.90 | -$3.60 | +7.7% | $0.03B | $0.04B | -19.3% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$4.05 | -$3.90 | +3.7% | $0.04B | $0.04B | +1.5% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$1.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$1.24
EPS Est.
-$1.45
EPS Surpr.
+14.5%
Revenue
$0.04B
Q1 FY2026
Feb 12, 2026Beat
EPS Actual
-$2.23
EPS Est.
-$2.26
EPS Surpr.
+1.3%
Revenue
$0.03B
Q4 FY2025
Nov 3, 2025Miss
EPS Actual
-$3.82
EPS Est.
-$3.47
EPS Surpr.
-10.1%
Revenue
$0.04B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$4.32
EPS Est.
-$3.80
EPS Surpr.
-13.7%
Revenue
$0.04B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$2.77
EPS Est.
-$4.21
EPS Surpr.
+34.2%
Revenue
$0.03B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
-$3.60
EPS Est.
-$3.90
EPS Surpr.
+7.7%
Revenue
$0.03B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$3.90
EPS Est.
-$4.05
EPS Surpr.
+3.7%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $1.86 | $2.15 | $2.57 | 1 |
| Q3 FY2030 | $1.76 | $2.04 | $2.44 | 1 |
| Q2 FY2030 | $1.62 | $1.88 | $2.25 | 1 |
| Q1 FY2030 | $1.47 | $1.70 | $2.03 | 1 |
| Q4 FY2029 | $1.25 | $1.45 | $1.73 | 1 |
| Q3 FY2029 | $1.05 | $1.21 | $1.45 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.3B | $0.3B | $0.3B | 3 |
| Q3 FY2030 | $0.2B | $0.3B | $0.3B | 2 |
| Q2 FY2030 | $0.2B | $0.2B | $0.3B | 2 |
| Q1 FY2030 | $0.2B | $0.2B | $0.3B | 3 |
| Q4 FY2029 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2029 | $0.1B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +14.5% | $8.85 | $8.90 | +0.56% |
| ▲ Q1 FY2026 | Feb 12, 2026 | +1.3% | $7.37 | $8.94 | +21.30% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -10.1% | $5.80 | $6.07 | +4.66% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -13.7% | $3.94 | $3.77 | -4.31% |
| ▲ Q2 FY2025 | May 12, 2025 | +34.2% | $6.01 | $6.15 | +2.33% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +7.7% | $9.45 | $9.00 | -4.76% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +3.7% | $14.00 | $12.69 | -9.36% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +31.0% | $13.07 | $12.60 | -3.60% |
Q2 FY2026+0.56%
Report Date
May 14, 2026
EPS Beat/Miss
+14.5%
Price Before
$8.85
Price After
$8.90
Q1 FY2026+21.30%
Report Date
Feb 12, 2026
EPS Beat/Miss
+1.3%
Price Before
$7.37
Price After
$8.94
Q4 FY2025+4.66%
Report Date
Nov 3, 2025
EPS Beat/Miss
-10.1%
Price Before
$5.80
Price After
$6.07
Q3 FY2025-4.31%
Report Date
Aug 11, 2025
EPS Beat/Miss
-13.7%
Price Before
$3.94
Price After
$3.77
Q2 FY2025+2.33%
Report Date
May 12, 2025
EPS Beat/Miss
+34.2%
Price Before
$6.01
Price After
$6.15
Q1 FY2025-4.76%
Report Date
Feb 19, 2025
EPS Beat/Miss
+7.7%
Price Before
$9.45
Price After
$9.00
Q4 FY2024-9.36%
Report Date
Nov 5, 2024
EPS Beat/Miss
+3.7%
Price Before
$14.00
Price After
$12.69
Q3 FY2024-3.60%
Report Date
Aug 6, 2024
EPS Beat/Miss
+31.0%
Price Before
$13.07
Price After
$12.60
Avg Beat Reaction+1.08%
Avg Miss Reaction+0.18%
Beat Rate6 / 8 quarters
Largest Move+21.30% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KPTI ends December
Karyopharm Therapeutics Inc. (KPTI) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-1.24 — beating the analyst consensus of $-1.45 by +14.5%. KPTI has beaten EPS estimates for 2 consecutive quarters. The next KPTI earnings date is expected around September 1, 2026.
Each quarter, investors track KPTI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KPTI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KPTI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KPTI earnings · 5 questionsKaryopharm Therapeutics Inc.'s next earnings report is expected around September 1, 2026. KPTI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KPTI historically reports after market close (AMC).
KPTI earnings datewhen is KPTI earningsKPTI next earnings datewhen does KPTI report earningsKPTI earnings calendar
▸ Source: FMP · Karyopharm Therapeutics Inc. SEC filings · US GAAP · Karyopharm Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026